A Tough Menu to Digest<br />By Rev Shark<br />RealMoney.com Contributor<br />11/30/2009 8:37 AM EST<br /><br /> Any idiot can face a crisis -- it's day-to-day living that wears you out.<br /> -- Anton Chekhov<br /><br />After some typical holiday trading last Wednesday, the Dubai debt dustup caught many market players by surprise during Friday's short session. Although we were solidly negative all day, we moved steadily higher after the big opening gap down, and that took some of the sting out of the action.<br /><br />It is very difficult to read much into the trading around the holidays, especially as market players are still trying to sort out the repercussions of the Dubai problems. This morning the overseas action isn't doing much to clarify things. While Asian markets have bounced quite sharply, the European bourses are down around 1% or more. While there seems to be some lessening of anxiety over Dubai, there are still concerns -- issues as diverse as orders for new aircrafts and foreign real estate holdings are affected.<br /><br />Even if the Dubai problem weren't so murky, we still have some mixed fundamentals to navigate. Retail sales reports show that while there were many more shoppers this year compared to last, they spent quite a bit less money. The net result was just a very minor increase in total sales over last year. Consumers are obviously still cautious, and who can blame them?<br /><br />The technical picture of the market is a bit mixed as well. Although we have seen a continued strong inclination to buy on weakness, there has been narrower leadership, underperformance in small-caps and relative weakness in the financial sector.<br /><br />Helene Meisler has also pointed out recently how sentiment surveys indicate a very high level of complacency and are at levels that often occur near tops. So many folks are looking for positive year-end seasonality that it isn't particularly surprising that there is a high level of optimism, but as we saw Friday, seasonality is no sure thing.<br /><br />Although the considerations discussed above are important, what the market has really been focused on lately is the dollar. We have an extremely strong inverse correlation with the dollar recently. Any weakness in the dollar has buyers jumping into oil, gold and commodity stocks, and they drag the rest of the market along with them.<br /><br />What really caused the gap down on Friday was strength in the dollar; as the dollar weakened during the rest of the day, the market followed along in lock step. This morning the dollar is strengthening a bit again, and that is what helped Asian exports jump and is putting pressure on the indices in the early going.<br /><br />Even if weakness in the dollar bolsters the indices again, we need better action in financials and for the strength to broaden out, especially to the smaller-caps. Pockets of speculative action still exist, particularly in some China and solar energy names, but it is limited and that is a bit troubling.<br /><br />We'll have to keep a close watch on the dollar. Ironically, the focus on the dollar has given us a market that is highly correlated with strength in gold. Gold is usually considered to be a safe haven in times of uncertainty, but in this market higher gold has been an indication that the market is in good shape. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />Select steel names showing strength boosted by Goldman upgrade of the U.S. steel sector: X +3.6% (raised to Conviction Buy from Buy by Goldman- DJ), AKS +2.7%, NUE +2.4%... Select auto related names showing strength: TTM +3.1%, TM +2.6%... Other news: CLRT +26.4% (granted exclusive license to commercialize cancer biomarker by Minerva Biotechnologies), NVAX +8.0% (completes ernrollment in Phase IIa study of seasonal influenza vaccine in older adults), VPRT +7.3% (terminates all membership program offerings and reaffirms financial guidance), MTU +5.0% (still checking), ALTH +4.5% (United States Patent and Trademark Office has issued a patent for the use of FOLOTYN for the treatment of T-cell lymphoma), SQNM +4.1% (still checking), DPTR +3.3% (announces review of strategic alternatives)... Analyst comments: AOB +2.8% (resumed with a Buy at Brean Murray), DE +2.7% (upgraded to Neutral from Underweight at JP Morgan and upgraded to Outperform at Wells Fargo), EFII +2.7% (upgraded to Buy at Brean Murray), GENZ +2.3% (upgraded to Buy at Citigroup), USB +2.0% (upgraded to Outperform at Baird), ANF +2.0% (upgraded to Outperform at FBR), AFL +1.8% (upgraded to Outperform at Credit Suisse; tgt raised to $60), HBC +1.0% (initiated with Outperform at FBR).<br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: NRGY -1.0% (light volume)... Select European financials trading lower: LYG -7.2%, ING -5.2%, RBS -3.7%, AIB -2.1%... Select metals/mining named showing continued weakness: KGC -1.9%, GOLD -1.7%, RTP -1.4%, AU -1.3%, AEM -1.1%... Select oil/gas related names seeing early weakness: BP -2.0%, RDS.B -1.9%, STO -1.8%, CHK -1.3%, HERO -1.2%... Select Europeans drug names trading lower: GSK -1.6% (to cut drug prices in developing countries - FT.com), AZN -1.3%, SNY -1.1% (European Commission has granted marketing authorization for Multaq (dronedarone - 400mg Tablets) in all 27 European member states)... Other news: THRX -4.8% (announces that EMEA has completed the validation phase for the Telavancin MAA for the treatment of nosocomial pneumonia and complicated skin and soft tissue infections), RSO -2.9% (Resource Capital announces common stock follow-on offering of ~ $50 mln), CHL -1.4% (halts WAP tolls in clean up act - Pacific Epoch)... Analyst comments: AIG -3.4% (tgt cut to $12 from $20 at Bernstein), SVU -2.2% (downgraded to Underweight at Morgan Stanley), BKC -1.5% (downgraded to Underperform at Wedbush Morgan), BIDU -1.1% (downgraded BIDU to Market Perform from Outperform at Bernstein).